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Summary A number of biological factors have been identified which correlate with prognosis in neuroblas-
toma. Among these are genetic aberrations, including ploidy, deletions of chromosome lp and N-myc
amplification. Conventional methods of detecting these changes, such as tissue culture for karyotyping and
Southern blotting, are time-consuming and yield interpretable results in only a small proportion of cases. We
have developed interphase fluorescence in situ hybridisation for use on tumour imprints and bone marrow
smears, allowing rapid visualisation of the relevant genetic changes. Valuable prognostic information is
therefore available in a few days: the results in our cases were later confirmed by conventional methods. In the
foreseeable future it will be possible to define distinct prognostic categories on the basis both of this genetic
information and other parameters, and separate therapeutic strategies may then be employed for the different
patient groups.
Neuroblastoma is the most common extracranial solid malig-
nant tumour of children. It arises from the embryonal neural
crest tissue and affects approximately 1 in 10,000 individuals
(Donner, 1991). The prognosis in neuroblastoma is variable,
and many studies have been carried out which correlate
clinical and biological factors with outcome (Evans et al.,
1987; Oppedal et al., 1988). Prognostic variables include age,
stage, histopathological appearance, partial monosomy of lp
(Christiansen & Lampert, 1988), ploidy, N-myc amplification
(Bourhis et al., 1991) and nerve growth factor receptor exp-
ression (Brodeur, 1993). In addition, serum concentrations of
ferritin, neuron-specific enolase and lactate dehydrogenase
have been found to correlate with clinical outcome (Silber et
al., 1991).
It now seems likely that neuroblastoma patients may be
classified in two therapeutic categories according to
biological features (Woods et al., 1992). Favourable prog-
nosis in neuroblastoma is associated with young age (less
than 1 year) and early stage (1 or 2a), triploid karyotype,
lack of lp abnormalities and absence of N-myc gene
amplification. Patients with these features have an excellent
outcome with little or no therapy. Unfavourable prognosis is
associated with older age, advanced stage (2b, 3 or 4),
pseudodiploid and tetraploid karyotypes, lp deletions and
N-myc amplification. In these patients the outcome is
relatively poor despite aggressive multiagent chemotherapy
and, in some cases, marrow ablative treatment with bone
marrow transplantation. Ultimately it should be possible to
use the most discriminating of these factors to define interna-
tional criteria for the diagnosis and staging of neuroblastoma
and its response to treatment (Brodeur et al., 1993).
N-myc, a proto-oncogene located at 2p23-24 (Schwab et
al., 1984), may be amplified up to 500 times in neuroblas-
toma, usually as double minutes or as chromosomally
integrated homogeneously staining regions. N-myc
amplification has been shown to correlate strongly with rapid
tumour progression and poor prognosis independent of the
other poor prognostic factors with which it is frequently
associated. However, amplification is not found in all poor-
risk neuroblastomas: it is present in about 40% of stage 4
tumours. Similarly, deletions of chromosome lp and
pseudodiploidy have been found to be independent markers
of poor prognosis (Hayashi et al., 1989). It is now thought
that del(lp) occurs less frequently than originally described,
because early studies concentrated on advanced tumours and
established cell lines, in which more than 70% of the
tumours had deletions (Brodeur & Fong, 1989). This abnor-
mality is much less commonly found in stage 1 and 2
tumours (Hayashi et al., 1989). The consensus deletion has
been mapped to lp36.1-2 (Weith et al., 1989), which may be
the site of a tumour-suppressor gene, or anti-oncogene,
important in neuroblastoma (Schwab, 1991).
The presence of del(lp), N-myc amplification, or
pseudodiploid or tetraploid karyotype, can be used at diag-
nosis to identify patients who will do badly despite an appar-
ently favourable clinical picture. Intensive treatment can then
be specifically given to this subgroup of patients (Look et al.,
1991). A relevant and crucial observation has been that the
N-myc status of a particular tumour does not evolve or
regress during the course of the disease. One study by
Brodeur and Fong (1989) showed more than 95% concor-
dance within individuals from site to site and time to time.
Tumours therefore have a specific N-myc copy number at
diagnosis which remains constant throughout the disease.
Similarly, tumours with good-prognosis karyotypic changes
have not been demonstrated to evolve to a poor prognostic
group, nor have those with poor-prognosis changes reverted
to a more favourable prognostic group.
Conventional cytogenetic analysis of neuroblastomas takes
between 2 and 4 weeks and is limited by a very low success
rate with tissue culture, which yields few metaphases, often of
poor quality. Typically less than 30% of neuroblastomas can
be analysed in this way, though a higher figure may be
achieved if heavily infiltrated bone marrow is used. In addi-
tion, culturing may encourage overgrowth of normal stromal
cells, or may select for a non-representative subgroup of
tumour cells with a growth advantage. Recently, interphase
cytogenetics has been used to circumvent this problem
(Christiansen et al., 1992). This technique can be applied to
nuclear preparations from cultured cells, from collagenase
disaggregated tissue, and from specially treated paraffin sec-
tions (Stock et al., 1993).
We report a new, rapid and direct method for the deter-
mination of N-myc amplification, chromosome 1 copy
number, presence of lp deletion and ploidy using
fluorescence in situ hybridisation (FISH) on tumour imprints
made directly onto glass slides, and on standard bone mar-
row smears.
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Materials and methods
Primary neuroblastoma samples were obtained by needle or
Trucut biopsy or open surgery and fresh tissue from all
samples was sent to the Royal Victoria Infirmary, Newcastle-
upon-Tyne, UK, for N-myc Southern blotting, culture and
karyotyping, under the aegis of the Neuroblastoma Commit-
tee of the United Kingdom Children's Cancer Study Group
(UKCCSG). In each case the diagnosis conformed with inter-
nationally agreed criteria (Brodeur et al., 1993) and his-
tological sections were reviewed by the UKCCSG's his-
tological review panel. Imprints were made directly onto
silane-coated slides using a dry, blood-free, newly cut surface
of the fresh, unfixed biopsy material. This was done as soon
as possible after removal of the tumour from the patient,
either at the hospital of origin or after transport in tissue
culture medium (RPMI-1640) to this laboratory. When possi-
ble, depending on sample size, at least six imprints were
made of each specimen. Slides made elsewhere were sent, air
dried and unfixed, by first class mail. Bone marrow slides
were also sent when an aspirate had been performed. Dry
slides were then fixed in 100% methanol for a minimum of
10 min, dried, and examined by phase-contrast microscopy to
ascertain the amount of debris present and the number of
tumour nuclei in the preparation. Slides were then washed
briefly in 70% glacial acetic acid to remove debris and cyto-
plasm, and immediately rinsed again in methanol. Further
microscopic examination showed whether the acetic acid
treatment had been adequate. If necessary this was cautiously
repeated: on some slides 100% acetic acid was used. Slides
were finally dehydrated through an ethanol series. Before
fluorescence in situ hybridisation the slides were baked at
65°C for about 4 h.
Neuroblastoma lines PCF, IMR32 and Kelly (obtained
from J. Kemshead, ICRF, Bristol, UK) were cultured in
Dulbecco's modified Eagle medium (DMEM) containing
10% fetal calf serum (FCS) and 1% non-essential amino acid
supplement at 37°C with 10% carbon dioxide. To obtain
metaphase spreads the cells were incubated for 1-2 h with
colcemid at 0.04 jIgml-', detached with trypsin and
resuspended in 75 mM potassium chloride for 10 min. Fixa-
tion was in 3:1 methanol-glacial acetic acid and nuclei were
dropped onto cleaned glass slides.
Synchronised interphase preparations were obtained from
the neuroblastoma lines and from human foreskin fibro-
blasts, cultured as above, by adding thymidine at 300lagml-'
to block confluent cell cultures. This was washed out after
16 h and the cells left a further 8 h before harvesting as
described.
DNA probes
A plasmid probe for N-myc, pNb-9, consisting of a genomic
HindIII fragment of 15 kb in pBR322, was obtained from M.
Schwab, Heidelberg, Germany. The probe pUCI.77 is a
satellite III repetitive DNA located in the heterochromatic
region of chromosome 1 (lql2) (Cooke & Hindley, 1979).
CT4-1 is a 35 kb cosmid clone isolated from a library using a
plasmid-subcloned DNA probe pl-24, also from M. Schwab,
which maps close to the consensus deletion at lp36.1-2. A
centromere probe p4.4 for chromosome 8 (M. Rocchi & A.
Baldini, unpublished data) was used as a control and to
obtain additional information about ploidy. DNA was
labelled by nick translation with biotin-1 -dATP (BRL Bio-
nick kit) according to the instructions of the supplier. The
probes were purified through a Sephadex G50 column to
remove free nucleotides and precipitated with salmon sperm
DNA and Escherichia coli tRNA prior to use for in situ
hybridisation.
In situ hybridisation
Hybridisation and detection were performed according to our
modification of the technique described by Pinkel et al.
(1986) and Taylor et al. (1993). Nuclei on slides were
denatured immediately before hybridisation in 70% forma-
mide, 2 x SSC (1 x SSC is 0.15 M sodium chloride, 0.015 M
sodium citrate), pH 7, at 37C for 3 min and then dehydrated
through an ethanol series of 70%, 95% and absolute ethanol
for 3 min each.
An 80 ng aliquot of each biotinylated cosmid probe and
60 ng of each centromere probe were mixed separately with
3jig of Cot-l DNA (Gibco BRL) to reduce signal from
repetitive sequences. The probe/competitor mixtures were
vacuum dried under ethanol and resuspended in 11 jil of
hybridisation mix (10% dextran sulphate, 2 x SSC, 50% for-
mamide, 1% Tween 20, pH 7). These were denatured for
5 min at 75°C, chilled on ice and allowed to reanneal for up
to 3 h at 37°C before being applied to denatured slides.
Separate imprints of the tumours were used for each of
pNb-9, pUCI.77, CT4-1 and p4.4. Hybridisation was per-
formed overnight at 37°C under sealed coverslips.
Probe detection
The slides were washed first in 50% formamide, 2 x SSC,
pH 7, followed by 2 x SSC, pH 7, three times each at 42°C,
then once in 4 x SSC, 0.05% Tween 20, pH 7 (SSCT). Slides
were preincubated with low-fat dried milk (Marvel)
(SSCTM). Detection of the biotinylated signal was carried
out by incubation with 5 LIml-' fluorescein isothiocyanate
(FITC)-conjugated avidin DCS (Vector Labs) in SSCTM for
30-40 min at 37°C. The signal was amplified by incubation
with 5 jig ml-' biotinylated anti-avidin for 30 min and a
second round of FITC-avidin DCS. Between the incubations
the slides were washed three times in SSCT at room
temperature for 3 min. Finally they were washed in
phosphate-buffered saline and dehydrated with ethanol.
Nuclei were counterstained with 0.5jlg ml-' propidium
iodide in Citifluor antifade solution (Citifluor, London, UK).
Images were photographed using a Zeiss Axiophot micro-
scope with Zeiss filter set 9.PRO and Fujicolor 400 ASA
print film.
Evaluation ofFISH results
Each of the four probes was hybridised onto separate im-
prints or bone marrow smears. If both imprints and smears
were available for an individual patient then all four probes
were hybridised to both sets of slides. An extra slide was
stained with Giemsa or May-Grunwald-Giemsa (MGG) so
that a parallel assessment of morphology could be made
allowing identification of tumour cells.
The neuroblastoma cells in these preparations were fre-
quently single, but often there was nuclear clumping. It was
necessary to include clumped nuclei in the study, but if the
nuclei were overlapping, as opposed to adjacent, they were
excluded. In some parts of the slides red blood corpuscles
were still present. These take up FITC non-specifically, so
when they were overlapping a tumour cell that cell had to be
excluded. The signals counted in each nucleus were of equal
intensity to each other, though there was slight variation
from cell to cell. Minor hybridisation spots and background
fluorescence were discounted. Signals had to be completely
separate from one another to be included; paired spots close
together were counted as one signal.
Inevitably, given the material from which these prepara-
tions were made, there was an admixture of tumour cells and
normal stromal or haemopoietic cells on each slide which
varied from one area to another. It was meaningless,
therefore, to include a preset number of random nuclei and
calculate average signal numbers. Only the cells which were
considered most likely to be tumour cells, after examination
of the Giemsa-stained slide of the same preparation, were
included. In fact, the proportion of non-tumour cells in the
tumour imprints was very low (<15%), whereas in some
bone marrow smears it was considerably higher. However
there was no difficulty in deciding which cells to include.
In all samples there were nuclei which did not react with
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three or more signals. Control experiments were carried out
with both centromere probes, CT4-1 and pNb-9, using
human foreskin fibroblast (HFF) nuclei and examining 600
nuclei for signal number. In the tumour imprints and bone
marrow smears at least 50, and preferably 100, nuclei were
examined which were believed to be of tumour origin. The
hybridisation was repeated using more probe DNA in those
cases in which <70% of nuclei showed a consistent result. In
practice, just one of the cases reported below required a
repeat hybridisation for CT4-1 in order to achieve this
result.
The inclusion of the chromosome 8 centromere probe
meant that those cases with three or four copies of
chromosome 1 could be more securely classified as triploid or
tetraploid rather than merely trisomic or tetrasomic for
chromosome 1. Chromosome 8 was chosen as it is not
specifically duplicated or deleted in neuroblastoma, and
because the probe available is reliable and specific.
Results
FISH on normal HFF nuclei and neuroblastoma cell lines
The sensitivity of the chosen probes was assessed by applying
them to preparations of normal HFF nuclei and examining
600 nuclei. Imprints of similar normal tissue or bone marrow
smears containing chromosomally normal but morpho-
logically identifiable non-haemopoietic cells were not readily
available for comparison. The chromosome 1 centromere
probe, pUCl.77, produced two clear signals in 78% of nor-
mal nuclei. In addition, 2% showed no signal, 14% showed
one signal, 3% three signals and 3% four signals. The second
centromere probe, p4.4, produced two signals in 83% of
normal nuclei. Proportions for no signal, one, three and four
signals were 0%, 10%, 2% and 5% respectively. Using the
distal lp probe, CT4-1, 80% of the nuclei displayed two
hybridisation signals, <1% no signal, 5% one signal, 4%
three signals, 9% four signals and 2% >4 signals.
The neuroblastoma line PCF was used in order to be
certain that the lp probe, CT4-1, lay distal to the breakpoint
at lp36. This cell line has four copies of chromosome 1, two
of which have a deletion of the tip of Ip. It was clearly
demonstrated that CT4-1 lay in the deleted region by hyb-
ridising pUCI.77 and CT4-1 together to metaphase spreads
(Figure 1). In addition, interphase preparations hybridised
with CT4-1 alone showed two signals in approximately 80%
of nuclei.
Two discrete signals were seen in 84% of HFF nuclei using
the N-myc probe pNb-9. Nuclei from two neuroblastoma cell
lines known to have amplification of N-myc were prepared.
IMR32 has approximately 20 copies per cell of N-myc, while
Kelly has 100 copies per cell. This produces a very charac-
teristic picture in 90% of interphase nuclei (Figures 2 and 3),
which cannot easily be mistaken for background
fluorescence. However, interphase studies will not reliably
detect N-myc amplification of less than 20 copies per cell as
the signal may be weak and sparsely distributed in the
nucleus. Low-level amplification may be observed in neuro-
blastoma, but this is a rare occurrence of uncertain prognos-
tic value. In reality, tumours with amplification of N-myc
usually have a large number of copies and are easily detected
by this method.
The six cases described in detail below are a representative
sample chosen to show the various combinations of genomic
abnormalities we most frequently observed. We are con-
tinually adding to the number of tumour samples analysed,
and so far we have been able to obtain interpretable results
in 93% of tumour imprints and 88% of bone marrow smears
(data not shown).
FISH on tumour imprints and bone marrow smearsfrom
patients (Table I)
Case I A 3-day-old boy presented with a stage 2 abdominal
neuroblastoma (Brodeur et al., 1988). This was resected when
the patient was 2 weeks old and found to have unfavourable
histology, according to the criteria of Shimada et al. (1984).
Tumour imprints were made from the resected material.
Subsequently he developed hepatic metastases and was rec-
lassified as stage 4. Southern blotting of the primary tumour
showed one copy of N-myc. Suitable metaphases for
karyotyping were not obtained. In situ hybridisation with
pNb-9 showed no signal typical of N-myc amplification in
any of the tumour nuclei examined. There were three signals
from pUCl.77 and CT4-1 in over 70% of tumour nuclei,
implying that there were three copies of chromosome 1 pres-
ent which were complete with no deletion at lp36 (Figure 4).
The chromosome 8 centromere probe showed two popula-
tions of cells, with four copies in 45% of nuclei and three
copies in 41%. These data suggest that the tumour has a
complex karyotype.
Case 2 A 3-week-old boy presented with stage 4s neuroblas-
toma with an extensive abdominal primary and hepatic
metastases. Histology was favourable. Southern blotting
revealed a single copy of N-myc, but no suitable metaphases
were obtained for karyotyping. Imprints made from the
biopsy specimen before it was subjected to these tests were
investigated. Three copies of each of the probes pUCI.77,
CT4-1 and p4.4 were seen in over 70% of nuclei (Figure 5),
indicating that the tumour was probably triploid. There was
no evidence of N-myc amplification, and in many nuclei three
single copies of pNb-9 were present (Figure 6). The patient
was observed without therapy and the tumour regressed
spontaneously.
Table I Comparison of results obtained from cytogenetic, Southern blot and FISH analyses of neuroblastomas
Case Cytogenetics results Southern blot FISH results
no. Ploidy and Chr. I changes for N-myc Ploidy and chr. 1 changes N-myc
1. Karyotype not obtained No amplification Complex: triploid/tetraploid. No amplification
Three copies chr. 1. No del(lp)
2. Karyotype not obtained No amplification Triploid. Three copies chr. 1. No amplification
No del(lp)
3. Two populations: diploid/ No amplification 25-30% tetraploid with three No amplification
near tetraploid copies CT4-1, i.e. one del(lp).
70-75% diploid, no del(lp)
4. Two populations: diploid/ No amplification Complex: tetrasomy chr. 1 No amplification
near tetraploid 70%; trisomy chr. 1 24%;
trisomy chr. 8 75%. Del(lp)
in tetraploid clone
5. Pseudodiploid No amplification Diploid with no del(lp) No amplification
Chr. 1 normal
6. Pseudodiploid Twenty copies of Diploid with deletion Definite
Unbalanced t(1;11) with N-myc of lp amplification
loss of lp448 C.P.F. TAYLOR et al.
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Figure 1 (Top left) Metaphase from neuroblastoma line PCF with chromosome 1 centromere and CT4-1 showing four copies of
chromosome 1, only two of which have a distal signal on lp (i.e. two deletions of lp). Figure 2 (Top centre) N-myc on IMR 32
interphase - typical appearance of 20 copies of N-myc. Figure 3 (Top right) N-myc on Kelly interphase - 100 copies of N-myc.
Figure 4 (Bottom left) Case 1 imprint with chromosome 1 centromere showing three signals per nucleus. Figure 5 (Bottom
centre) Case 2 imprint with CT4-1 showing three signals per nucleus (yellow nuclei are red blood corpuscles showing non-specific
uptake of FITC). Figure 6 (Bottom right) Case 2 imprint with N-myc probe showing three small signals in most nuclei.
Case 3 This 4-year-old boy was diagnosed as having stage 4
neuroblastoma when he presented with a thoracoabdominal
primary tumour and bone, bone marrow and pleural metas-
tases. A bone marrow aspirate was carried out and smears
made. No other biopsy material was available. An MGG-
stained marrow smear showed complete infiltration with
neuroblastoma cells. Some of the aspirated marrow was used
for Southern blotting for N-myc, which showed a single
copy, and some was cultured for metaphase preparation. The
chromosome spreads were not of sufficient quality for full
karyotyping, but counting was possible and revealed that
there were two cell populations. One had an apparently
normal 46,XY karyotype, while the other had a near-
tetraploid karyotype with chromosome counts varying
between 82 and 89. It was not possible to comment on the
presence of structural rearrangements as the chromosome
morphology was poor. FISH was performed directly on the
bone marrow smears, which showed no evidence of N-myc
amplification using pNb-9. The centromere probe pUCl.77
showed that there were two populations of tumour cells:
approximately 25-30% were large and most of these showed
four chromosome 1 centromere signals; the remaining
70-75% were smaller and had two signals. The distal lp
probe gave two signals in the smaller nuclei but a maximum
of three signals in the large cells. The chromosome 8 cen-
tromere probe confirmed that there were two populations of
tumour cells with 29% showing four signals and 65% only
two signals (in addition 3% showed three signals and 3%
one signal) (Figure 7). The results of the in situ hybridisation
therefore correlated well with those from other techniques,
showing that there was no N-myc amplification but that the
tumour contained a pseudodiploid clone with a probable
del(lp).
Case 4 This girl aged 7 years relapsed with bone marrow
disease 5 years after diagnosis of a stage 4 neuroblastoma. A
bone marrow aspirate was performed, but a solid tumour
biopsy was not available. Southern blotting showed a single
copy of N-myc. Karyotyping showed that there were two
populations of cells, one with an apparently normal 46,XX
karyotype and the other with a near-tetraploid complement
of 96-97 chromosomes per cell. In many of these cells four
copies of chromosome 1 were observed but the chromosome
morphology was not of high quality and no definite rear-
rangements of lp were identified. An MGG-stained smear of
the marrow aspirate showed that the neuroblastoma cells
were mainly in clumps, many of them mechanically dis-
rupted. FISH was performed directly on these preparations.
The N-myc probe clearly showed two signals in most of the
tumour nuclei, with no evidence of any amplified N-myc
signal. Probe pUCI.77 produced four signals in 70% of the
tumour nuclei, and three signals in 24%. The chromosome 8
centromere probe showed three signals in 75% of nuclei
(Figure 8). The distal cosmid for lp36, CT4-1, showed a
maximum of three signals. These results indicated a complex
karyotype, including chromosome 1 tetrasomy, with a distal
lp deletion in one copy.
Case S This boy was diagnosed as having a stage 4 neuro-
blastoma at age 7 years and 6 months, when he presented
with a primary adrenal tumour and bone marrow metastases.
Both a tumour biopsy and a bone marrow aspirate were
performed. Southern blotting showed that there was no
amplification of N-myc. Abnormal metaphases were obtained
from both the tumour and the marrow, and showed a
chromosome count of 47 with several structural alterations
involving chromosomes 3, 5 and 7. Additional changes inFISH FOR DETECTION OF PROGNOSTIC GENETIC FACTORS IN NEUROBLASTOMA 449
Figure 7 (Top left) Case 3 marrow with chromosome 8 centromere showing four signals in large tumour nuclei and two in smaller
tumour nuclei. Figure 8 (Top right) Case 4 - disrupted nuclei from marrow smear with chromosome 8 centromere showing three
signals per nucleus. Figure 9 (Bottom left) Case 6 imprint with chromosome 1 centromere showing two signals per nucleus.
Figure 10 (Bottom centre) Case 6 imprint with CT4-1 showing only one signal in each nucleus, implying a deletion of
chromosome lp. Figure 11 (Bottom right) Case 6 imprint with N-myc probe showing multiple copies.
chromosomes 4 and 18 were seen only in tumour nuclei from
the bone marrow. In all the metaphases studied both
chromosomes 1 were grossly normal with no evidence of
short-arm rearrangements. MGG staining of the marrow
smears showed a heavy infiltration with tumour cells. The
N-myc probe pNb-9 produced two discrete signals in many
nuclei, but there was no evidence of gene amplification. Two
copies both ofchromosome 1 centromere and of the distal lp
probe, CT4-1, were seen in approximately 90% of nuclei.
The control centromere, p4.4, showed two signals in 94% of
nuclei. The quality of the in situ hybridisation tended to be
higher with the tumour imprints than with the marrow smears
as there was less background fluorescence, and very few areas
of non-tumour cells. The in situ results correlate well with the
results from Southern blotting and from culturing.
Case 6 This 4-year-old girl who had previously been treated
for a stage 4 neuroblastoma relapsed with a chest wall mass
and axillary lymphadenopathy. Biopsies were taken from
both sites and imprints were made. The results of Southern
blotting revealed amplification of N-myc with approximately
20 copies. The karyotype was approximately diploid, and
included an unbalanced t(l; 1) translocation with loss of
material from the distal portion of lp. Giemsa staining of
slides from the chest wall and an involved lymph node
showed large numbers of tumour cells, some of which were
disrupted in the process of making the slides. There were two
copies of pUCI.77 in over 90% of tumour nuclei (Figure 9),
and two copies of p4.4 in 81% of nuclei. With CT4-4 only
10% of nuclei showed two signals, while the majority, 79%,
showed only one signal, and a further 10% had no visible
signal (Figure 10). The appearance after hybridisation with
pNb-9 suggested a high number of copies of this probe
(Figure 1). The data from the in situ hybridisation therefore
agreed with the karyotyping and blotting results, and showed
that the tumour had both a deletion of Ip and N-myc
amplification.
Discussion
We have shown that fluorescence in situ hybridisation can be
used to detect N-myc amplification, ploidy and lp deletions
in direct tumour imprints or bone marrow smears from
neuroblastomas. This technique for visualising chromosomal
aberrations has produced results which correlate very well
with the results of conventional methods. N-myc
amplification was detected unequivocally using pNb-9, and
the results were confirmed by Southern blotting. The assess-
ment of ploidy and detection of chromosome 1p aberrations
using FISH entirely correlated with the findings from
karyotyping in the four cases in which it was available.
A great advantage of this method is that very little tumour
material is required compared with Southern blotting, FACS
sorting or tissue culture, and that the tissue can be saved and
used for these investigations, or for histology, after the im-
prints have been made. A further advantage is that the
results of these in situ experiments, from receipt of the tissue
to microscopy and assessment of the fluorescent signals, can
take as little as 3 working days to complete, which is more
rapid than other methods of obtaining the same information.
Histological variables such as haemorrhage, necrosis and
fibrosis, which confound the interpretation of results in blot-
ting techniques using tissue homogenates, become unimpor-
tant. Any tumour cells present on the slides, if not
immediately apparent, are identifiable if the morphology is450 C.P.F. TAYLOR et al.
studied on a similar Giemsa- or MGG-stained preparation. If
the number of slides available is limited, Giemsa staining can
be performed prior to FISH without significantly altering the
efficiency of hybridisation. Problems inherent in tissue cul-
ture, such as overgrowth of stromal cells, selection of non-
representative highly proliferative populations of tumour cells
and difficulty in producing chromosomes of adequate quality
for karyotyping, are avoided. In addition, the presence of
prognostic genetic factors is determined on tumour cells
alone, by counting signals in cells morphologically identified
as malignant, whereas most methods use pooled DNA, or
cell suspensions, containing both normal and malignant
cells.
The preparation of the imprints and marrow smears, in
order to make them suitable for FISH, is simple. Initially
silane-coated slides were used as these increase the chance of
the nuclei adhering to the slides throughout all the steps of
the procedure. However, it was found that after methanol-
acetic acid fixation and heating there was little difference in
the quality of the preparations between the two types of
slide. Furthermore, spreading of aspirated bone marrow onto
silane-coated slides was difficult as the liquid tended to form
globules, which in turn meant that drying was a problem and
that areas of cell crowding made morphological interpreta-
tion difficult. Acetic acid was chosen as a means of removing
cytoplasm and debris as it is simple and quick to use, and
had been found in other similar circumstances to be more
effective than proteinase K or pepsin, and to allow better
preservation of morphology (Hopman et al., 1989). Another
advantage of acetic acid over pepsin is that it tends to flatten
the cells onto the slide, which means that fluorescent signals
are more likely to be in the same plane as each other,
reducing the need for refocusing (Hopman et al., 1988). It is
essential that the imprints are made as soon as possible after
the biopsy is taken, as a delay of more than a few hours
causes considerable deterioration in the tissue.
We have described a technique which represents a step
forward in the assessment of prognosis in children with
neuroblastoma. The importance of various biological factors
as markers of aggressiveness of the disease has been recog-
nised for some time, and some form of measurement of these
variables has increasingly been carried out in the clinical trial
setting. At present, treatment protocols are not drawn up
using this information, but are still based solely on clinical
prognostic factors such as age at diagnosis and stage of
disease. The reasons for this are threefold. Firstly, although
many biological features have been identified for neuroblas-
toma which relate to prognosis, no study has yet determined
which are most discriminatory. The agreed goal of the Inter-
national Neuroblastoma Staging System and Response
Criteria Committee is to collect information on tumour histo-
logy, ploidy, N-myc gene copy number, chromosome ip
deletion and serum concentrations of neuron-specific enolase,
ferritin and lactate dehydrogenase for all neuroblastomas
(Brodeur et al., 1993). Analysis of these data will indicate on
which biological features therapeutic decisions should be
based. Secondly, the results of the investigations into N-myc
amplification, ploidy and lp deletion need to be available at
the time of diagnosis and commencement of treatment.
Thirdly, existing methods of evaluating these biological fac-
tors require more tissue than is frequently obtained, plus
expensive or specialised resources such as flow cytometry and
Southern blotting, which are not readily available in all
centres which are treating children with neuroblastoma. We
believe that our technique comes at a time when it is appro-
priate to start making therapeutic decisions in neuroblastoma
on the basis of biological as well as clinical factors. We also
feel that this simple and immediate method can provide
reliable results sufficiently quickly, at the time of diagnosis,
to be useful in determining which children should receive
early intensive chemotherapy. Finally, we believe that this
application of FISH should become accessible to all
clinicians practising in this field. The technique is simple,
and, unlike complex cytogenetic and molecular biological
studies, could be performed in routine service laboratories.
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